Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05077527 · ClinicalTrials.gov registry record · Phase 1
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
A Phase 1 study of HIV Infection and Recurrent Diffuse Large B-Cell Lymphoma, sponsored by AIDS Malignancy Consortium.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 5
- Study locations
NCT05077527 is a Phase 1 study of HIV Infection and Recurrent Diffuse Large B-Cell Lymphoma that is actively recruiting participants, run by AIDS Malignancy Consortium. The registered enrollment target is 20 participants, below the 243-participant average among 73 other HIV Infection trials with a reported enrollment target (92% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT05077527, a Phase 1 study of HIV Infection and Recurrent Diffuse Large B-Cell Lymphoma, is actively recruiting participants, sponsored by AIDS Malignancy Consortium.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 5
- Study locations
Study Summary
This phase I trial evaluates the side effects and usefulness of axicabtagene clioleucel (a CAR-T therapy) and find out what effect, if any, it has on treating patients with HIV-associated aggressive B-cell non-Hodgkin lymphoma that has come back (relapsed) or not responded to treatment (refractory). T cells are infection fighting blood cells that can kill tumor cells. Axicabtagene ciloleucel consists of genetically modified T cells, modified to recognize CD-19, a protein on the surface of cancer cells. These CD-19-specific T cells may help the body's immune system identify and kill CD-19-positive B-cell non-Hodgkin lymphoma cells.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- BIOLOGICAL Axicabtagene Ciloleucel
Study Locations (5)
California
- City of Hope Comprehensive Cancer Center - Duarte
Illinois
- University of Illinois at Chicago - Chicago
New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- The Ohio state University - Columbus
Utah
- Huntsman Cancer Institute, University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-02-13 |
| Est. Completion | 2029-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05077527
The ClinicalTrials.gov registry entry for NCT05077527 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 243-participant average among 73 other HIV Infection trials with a reported enrollment target (92% lower). The listed sponsor is AIDS Malignancy Consortium, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with HIV Infection appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT05077527 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT05077527 about?
NCT05077527 is a clinical study titled "Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma". This phase I trial evaluates the side effects and usefulness of axicabtagene clioleucel (a CAR-T therapy) and find out what effect, if any, it has on treating patients with HIV-associated aggressive B-cell non-Hodgkin lymphoma that has come back (relapsed) or not responded to treatment (refractory)....
What is the current status of trial NCT05077527?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-02-13. Estimated completion is 2029-01-31.
What conditions does trial NCT05077527 study?
This clinical trial studies the following conditions: HIV Infection, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Grade 3b Follicular Lymphoma.
What interventions are being tested in trial NCT05077527?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Axicabtagene Ciloleucel (BIOLOGICAL).
Who is sponsoring clinical trial NCT05077527?
This trial is sponsored by AIDS Malignancy Consortium, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05077527 being conducted?
This trial has 5 study locations across California, Illinois, New York, Ohio, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
RECRUITING · Phase 1
-
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 1
-
Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption
ACTIVE NOT RECRUITING · Phase 1
-
Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Twins Study of Gene Therapy for HIV Infection
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.